Tumor-associated autoantibodies as diagnostic and prognostic biomarkers |
| |
Authors: | Chang-Kyu Heo Young Yil Bahk Eun-Wie Cho |
| |
Institution: | 1.Cancer Biomarkers Development Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 305-806, Korea;2.Department of Biotechnology, Konkuk University, Cheongju 380-701, Korea |
| |
Abstract: | In the process of tumorigenesis, normal cells are remodeled to cancer cells and protein expression patterns are changed to those of tumor cells. A newly formed tumor microenvironment elicits the immune system and, as a result, a humoral immune response takes place. Although the tumor antigens are undetectable in sera at the early stage of tumorigenesis, the nature of an antibody amplification response to antigens makes tumor-associated autoantibodies as promising early biomarkers in cancer diagnosis. Moreover, the recent development of proteomic techniques that make neo-epitopes of tumor-associated autoantigens discovered concomitantly has opened a new area of ‘immuno-proteomics’, which presents tumor-associated autoantibody signatures and confers information to redefine the process of tumorigenesis. In this article, the strategies recently used to identify and validate serum autoantibodies are outlined and tumor-associated antigens suggested until now as diagnostic/prognostic biomarkers in various tumor types are reviewed. Also, the meaning of autoantibody signatures and their clinical utility in personalized medicine are discussed. BMB Reports 2012; 45(12): 677-685] |
| |
Keywords: | Biomarker Diagnostic Prognostic Tumor-associated autoantibody Tumor-associated autoantigen |
|
|